Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LARS1 | Q9P2J5 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | PLG | P00747 | 1/20 | 0.38 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.38 |
| ▸ | CCR4 | P51679 | 1/20 | 0.37 |
| ▸ | F2 | P00734 | 3/20 | 0.36 |
| ▸ | TPSAB1 | Q15661 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HTR7 | P34969 | 1/20 | 0.35 |
| ▸ | BCL2 | P10415 | 1/20 | 0.35 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.35 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.35 |
| ▸ | BCL2A1 | Q16548 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3090643 | 0.91 | LARS1 (0.43) | LARS1LMNAPLGF2ALDH1A1 | |
| SCHEMBL3103273 | 0.85 | LARS1 (0.39) | LARS1LMNAPLGF2ALDH1A1 | |
| SCHEMBL3103267 | 0.85 | LARS1 (0.39) | LARS1LMNAPLGF2ALDH1A1 | |
| SCHEMBL14999974 | 0.84 | LARS1 (0.49) | LARS1LMNAPLGF2TPSAB1 | |
| SCHEMBL3085973 | 0.84 | LARS1 (0.53) | LARS1LMNAPLGF2ALDH1A1 | |
| SCHEMBL3090411 | 0.84 | LARS1 (0.40) | LARS1LMNAPLGF2ALDH1A1 | |
| SCHEMBL3103667 | 0.84 | LARS1 (0.40) | LARS1PLGF2ALDH1A1KMT2A | |
| SCHEMBL3097141 | 0.83 | BCHE (0.39) | LARS1PLGALDH1A1KDM4E | |
| SCHEMBL3096206 | 0.82 | LARS1 (0.41) | LARS1LMNAPLGF2ALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL3091304 | 0.82 | LARS1 (0.37) | LARS1PLGF2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8461209-B2 | Malonic acid sulfonamide derivative and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-06-11 | — | — | US | disclosed |
| US-20100228026-A1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100228026-A1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | REN, AGTR2, AGTR1 | LARS1 1976/4885LMNA 3803/4885PLG 2448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.